Illumina, Inc.

DB:ILU Stock Report

Market Cap: €20.2b

Illumina Valuation

Is ILU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ILU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ILU (€126.94) is trading below our estimate of fair value (€128.18)

Significantly Below Fair Value: ILU is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ILU?

Key metric: As ILU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ILU. This is calculated by dividing ILU's market cap by their current revenue.
What is ILU's PS Ratio?
PS Ratio4.7x
SalesUS$4.39b
Market CapUS$20.77b

Price to Sales Ratio vs Peers

How does ILU's PS Ratio compare to its peers?

The above table shows the PS ratio for ILU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
SRT3 Sartorius
4.4x8.8%€13.4b
1SXP SCHOTT Pharma KGaA
3.9x10.4%€3.7b
GXI Gerresheimer
1.2x9.8%€2.4b
EVT Evotec
1.9x12.1%€1.5b
ILU Illumina
4.7x5.1%€20.8b

Price-To-Sales vs Peers: ILU is expensive based on its Price-To-Sales Ratio (4.7x) compared to the peer average (2.9x).

Price to Sales Ratio vs Industry

How does ILU's PS Ratio compare vs other companies in the European Life Sciences Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
ILU 4.7xIndustry Avg. 4.4xNo. of Companies6PS03.26.49.612.816+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ILU is expensive based on its Price-To-Sales Ratio (4.7x) compared to the European Life Sciences industry average (4.4x).

Price to Sales Ratio vs Fair Ratio

What is ILU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ILU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.7x
Fair PS Ratio4.4x

Price-To-Sales vs Fair Ratio: ILU is expensive based on its Price-To-Sales Ratio (4.7x) compared to the estimated Fair Price-To-Sales Ratio (4.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ILU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€126.94
€159.18
+25.4%
15.7%€245.55€116.93n/a25
Dec ’25€135.72
€156.35
+15.2%
16.1%€241.27€113.99n/a25
Nov ’25€137.78
€144.38
+4.8%
19.0%€231.69€96.54n/a24
Oct ’25€116.02
€134.26
+15.7%
20.2%€226.72€94.47n/a23
Sep ’25€118.44
€133.35
+12.6%
19.3%€217.51€94.37n/a23
Aug ’25€112.94
€135.97
+20.4%
22.3%€223.46€92.34n/a22
Jul ’25€97.72
€137.50
+40.7%
22.3%€225.91€93.35n/a22
Jun ’25€92.68
€142.91
+54.2%
23.8%€232.51€91.90n/a22
May ’25€115.34
€147.50
+27.9%
23.0%€237.52€93.88n/a23
Apr ’25€126.88
€147.62
+16.3%
23.4%€238.03€78.42n/a22
Mar ’25€129.18
€147.40
+14.1%
23.4%€238.08€78.44n/a22
Feb ’25€133.66
€142.46
+6.6%
29.8%€238.21€73.86n/a24
Jan ’25€127.68
€135.04
+5.8%
32.4%€233.70€45.29€128.3224
Dec ’24€99.99
€141.37
+41.4%
38.1%€239.69€46.10€135.7221
Nov ’24€100.08
€185.69
+85.5%
24.0%€300.22€94.41€137.7821
Oct ’24€129.78
€200.90
+54.8%
25.4%€300.80€94.59€116.0221
Sep ’24€155.82
€205.60
+31.9%
19.2%€293.10€138.26€118.4421
Aug ’24€172.56
€214.38
+24.2%
17.7%€292.12€133.59€112.9420
Jul ’24€170.98
€224.40
+31.2%
17.5%€307.84€137.43€97.7219
Jun ’24€184.84
€224.65
+21.5%
17.7%€308.92€137.91€92.6819
May ’24€185.68
€223.10
+20.2%
17.5%€304.44€136.73€115.3419
Apr ’24€213.75
€225.47
+5.5%
16.2%€279.36€139.68€126.8820
Mar ’24€186.68
€226.95
+21.6%
16.8%€282.09€139.65€129.1820
Feb ’24€196.26
€229.12
+16.7%
16.2%€275.97€147.18€133.6620
Jan ’24€185.52
€241.69
+30.3%
19.4%€330.19€150.94€127.6818

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 08:56
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/29
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Illumina, Inc. is covered by 58 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
James Francis MainwaringAtlantic Equities LLP
Catherine Ramsey SchulteBaird